Research
07 Nov 2025
5 minute read
Belgium’s leadership in Biopharma innovation
Time to act now
Belgium has a strong historical legacy in Biomanufacturing and Biopharma innovation. But our position is under pressure with recent regulatory changes, and macroeconomic and geopolitical dynamics. We should not be complacent. We need to act now to stay a frontrunner in the Biopharma sector. Deloitte has been on the ground in supporting the development of novel innovative therapies and strengthening competitiveness of national and regional ecosystems. This paper is a reflection on the field, the challenges and opportunities for the Belgian ecosystem to become the place where innovation in Biopharma chooses to stay and grow.
Belgium's Leadership in Biopharma Innovation
Our three key takeaways:
- Catalyze the talent development initiatives across regions to rapidly upskill the workforce with the appropriate toolbox in Biopharma and attract international first-class academic and entrepreneur profiles through stronger collaboration and faster work and residence permit approvals
- Deploy aggressive public and private capital to anchor domestic scale-up, attract international tier one venture capital funds, and update incentives to better support innovation in (bio)manufacturing and R&D technologies
- Build a patient-centric data backbone, designed to establish trustworthy rails for patient data usage, ensuring data ultimately services sciences, research and innovation and market access in a safe, transparent and patient-approved way.
